Long-term outcomes of prolonged fenticonazole therapy in patients with recurrent vulvovaginal candidiasis
Dobrokhotova Yu.E., Borovkova E.I., Burdenko M.V., Kovler S.E.
Objective: To study the effect of a prolonged course of topical therapy with fenticonazole for the prevention of recurrent vulvovaginal candidiasis in patients with the chronic recurrent course of the disease and to evaluate the recurrence-free course of vulvovaginal candidiasis during the following 6 months.
Materials and methods: The study included 206 female patients with recurrent vulvovaginal candidiasis. The patients received the following treatment: fenticonazole 600 mg topically was prescribed twice at 72 h intervals to the patients of the main group (n=96); then the patients of the 1st subgroup (n=36) received fenticonazole 600 mg once every 10 days for 3 months; the patients of the 2nd subgroup (n=30) received fenticonazole 600 mg twice at 72 h intervals once a month for 3 months; the patients of the 3rd subgroup (n=30) received fenticonazole 600 mg once every 10 days followed by two courses of PRP-therapy. The patients in the control group (n=110) were prescribed fluconazole 150 mg orally on days 1, 4 and 7, then 150 mg once a week for 3 months. The patients of the groups were comparable in age, body mass index, somatic and gynecologic diseases. The women were followed up for 3 months of maintenance therapy and then 6 months after the end of the treatment.
Results: There were no significant differences in the rate of recurrent vulvovaginal candidiasis in patients receiving systemic and topical therapy (p=0.66), but during a 3-month follow-up the rate of recurrence was considerably higher in the group of patients who received systemic treatment with fluconazole (p=0.043). The efficacy of therapy was 92.71% in the main group and there were no subsequent recurrences during the next 3 months in 87.5% of the patients. The efficacy of therapy was 94.55% in the control group, and there were no recurrences in 76.36% of the patients during the next 3 months. Recurrences were noted in 34.3% (33/96) of patients in the main group in 6 months after the end of the course of maintenance therapy, and recurrences were observed in almost every second case in the control group, namely, in 46.4% (51/110), respectively (p=0.039).
Conclusion: Topical and systemic therapy are equally effective in the treatment of recurrent vulvovaginal candidiasis. The rate of recurrence after the end of the treatment was significantly lower after topical use of fenticonazole compared to systemic administration of fluconazole.
Authors’ contributions: Dobrokhotova Yu.E. – developing the design of the study; Borovkova E.I., Burdenko M.V., Kovler S.E. – collecting the material, writing the article.
Conflicts of interest: Authors declare lack of the possible conflicts of interests.
Funding: The study was conducted without sponsorship.
Ethical Approval: The study was approved by the Ethical Review Board of the N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia.
Patient Consent for Publication: The patients provided an informed consent for the publication of their data.
Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Dobrokhotova Yu.E., Borovkova E.I., Burdenko M.V., Kovler S.E. Long-term outcomes of prolonged fenticonazole therapy in patients with recurrent vulvovaginal candidiasis.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (10): 148-157 (in Russian)
https://dx.doi.org/10.18565/aig.2024.241
Keywords
vulvovaginal candidiasis
Сandida albicans
recurrent vulvovaginal candidiasis
fluconazole
fenticonazole
platelet-rich plasma
References
- Sobel J.D. Recurrent vulvovaginal candidiasis. Am. J. Obstet. Gynecol. 2016; 214(1): 15-21. https://dx.doi.org/10.1016/j.ajog.2015.06.067.
- Workowski K.A., Bachmann L.H., Chan P.A., Johnston C.M., Muzny C.A., Park I. et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm. Rep. 2021; 70(4): 1-187. https://dx.doi.org/10.15585/mmwr.rr7004a1.
- Nyirjesy P., Brookhart C., Lazenby G., Schwebke J., Sobel J.D. Vulvovaginal candidiasis: a review of the evidence for the 2021 Centers for Disease Control and Prevention of sexually transmitted infections treatment guidelines. Clin. Infect. Dis. 2022; 74(Suppl_2): S162-S168. https://dx.doi.org/10.1093/cid/ciab1057.
- Доброхотова Ю.Э. Боровкова Е.И. Бурденко М.В. Оценка эффективности пролонгированного применения фентиконазола у пациенток с хроническим рецидивирующим вульвовагинальным кандидозом. Акушерство и гинекология. 2024; 1: 130-9. [Dobrokhotova Yu.E., Borovkova E.I., Burdenko M.V. Effectiveness of prolonged use of fenticonazole in patients with chronic recurrent vulvovaginal candidiasis. Obstetrics and Gynecology. 2024; (1): 130-9. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.303.
- Sobel J.D. Vulvovaginal candidosis. Lancet. 2007; 369(9577): 1961-71. https://dx.doi.org/10.1016/S0140-6736(07)60917-9.
- Cooke G., Watson C., Deckx L., Pirotta M., Smith J., van Driel M.L. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst. Rev. 2022; 1(1): CD009151. https://dx.doi.org/10.1002/14651858.CD009151.pub2.
- Guideline Development Group: Saxon C. (Lead Author), Edwards A., Rautemaa-Richardson R., Owen C., Nathan B., Palmer B., Wood C. et al. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019). Int. J. STD AIDS. 2020; 31(12): 1124-44. https://dx.doi.org/10.1177/0956462420943034.
- Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Ostrosky-Zeichner L. et al. Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2016; 62(4): e1-50. https://dx.doi.org/10.1093/cid/civ933.
- Collins L.M., Moore R., Sobel J.D. Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by Candida albicans. J. Low Genit. Tract. Dis. 2020; 24(1): 48-52. https://dx.doi.org/10.1097/LGT.0000000000000496.
- Российское общество дерматовенерологов и косметологов. Клинические рекомендации. Урогенитальный кандидоз. 2020. 26с. [Russian Society of Dermatovenerologists and Cosmetologists. Clinical guidelines. Urogenital candidiasis. 2020. 26c. (in Russian)].
- Sobel J.D., Wiesenfeld H.C., Martens M., Danna P., Hooton T.M., Rompalo A. et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N. Engl. J. Med. 2004; 351(9): 876-83. https://dx.doi.org/10.1056/NEJMoa033114.
- Инструкция по медицинскому применению лекарственного препарата Ломексин РУ ЛСР-008990/10 от 31.08.2010 (капсулы вагинальные); РУ ЛСР-002508 от 29.12.2011 (крем для вагинального и наружного применения). [Instructions for the medical use of the drug Lomexin RU LSR-008990/10 dated 08/31/2010 (vaginal capsules); RU LSR-002508 dated 12/29/2011 (cream for vaginal and external use). (in Russian)].
- Denning D.W., Kneale M., Sobel J.D., Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect. Dis. 2018; 18(11): e339-e347. https://dx.doi.org/10.1016/S1473-3099(18)30103-8.
- Chapple A., Hassell K., Nicholson M., Cantrill J. "You don't really feel you can function normally": women's perceptions and personal management of vaginal thrush". J. Reprod. Infant Psychol. 2000; 18(4): 309-19. https://dx.doi.org/10.1080/713683045.
- Nurbhai M., Grimshaw J., Watson M., Bond C., Mollison J., Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst. Rev. 2007; (4): CD002845. https://dx.doi.org/10.1002/14651858.CD002845.pub2.
- Sobel J.D. Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. Patient Prefer. Adherence. 2013; 8: 31-4. https://dx.doi.org/10.2147/PPA.S38984.
- Sanguinetti M., Cantón E., Torelli R., Tumietto F., Espinel-Ingroff A., Posteraro B. In vitro activity of fenticonazole against Candida and bacterial vaginitis isolates determined by mono- or dual-species testing assays. Antimicrob. Agents Chemother. 2019; 63(7): e02693-18. https://dx.doi.org/10.1128/AAC.02693-18.
- Muñoz Reyes J.R., Villanueva Reynoso C., Ramos C.J., Menéndez Vázquez J., Bailón Uriza R., Vargas A.J. Eficacia y tolerancia de 200 mg de fenticonazol vs 400 mg de miconazol en el tratamiento intravaginal de la vulvovaginitis micótica [Efficacy and tolerance of 200 mg of fenticonazole versus 400 mg of miconazole in the intravaginal treatment of mycotic vulvovaginitis]. Ginecol. Obstet. Mex. 2002; 70: 59-65. (in Spanish).
Received 30.09.2024
Accepted 14.10.2024
About the Authors
Yulia E. Dobrokhotova, Professor, Dr. Med. Sci., Head of the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1-9, +7(495)722-63-99, pr.dobrohotova@mail.ru, https://orcid.org/0000-0002-7830-2290Ekaterina I. Borovkova, Dr. Med. Sci., Associate Professor, Professor, Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1-9, +7(903)785-57-93, Katyanikitina@mail.ru, SPIN-code: 8897-8605,
https://orcid.org/0000-0001-7140-262X
Marina V. Burdenko, PhD, Associate Professor, Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1-9, +7(495)722-63-99, bmv-0306@rambler.ru, https://orcid.org/0000-0002-0304-4901
Sofia E. Kovler, 5th year student of the International Faculty, Pirogov Russian National Research Medical University, Ministry of Health of Russia,
117997, Russia, Moscow, Ostrovityanov str., 1-9, +7(927)236-36-12, ksonechka121@gmail.com, https://orcid.org/0009-0000-5995-4261
Similar Articles
